Publicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (152)

2024

  1. A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

    Annals of Oncology, Vol. 35, Núm. 8, pp. 707-717

  2. Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial

    British Journal of Dermatology, Vol. 191, Núm. 2, pp. 187-199

  3. Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain

    PharmacoEconomics - Open

  4. Developing Therapies for C3 Glomerulopathy Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group

    Clinical Journal of the American Society of Nephrology, Vol. 19, Núm. 9, pp. 1201-1208

  5. Durvalumab _ Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

    Clinical Cancer Research, Vol. 30, Núm. 4, pp. 824-835

  6. Enhancing the management of chronic diseases in clinical practice: The CARABELA methodology

    Journal of Healthcare Quality Research, Vol. 39, Núm. 5, pp. 336-339

  7. Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

    Frontiers in Neurology, Vol. 15

  8. Lack of awareness of systemic lupus erythematosus and its consequences in a cohort of moderate and severe patients in Spain: The LupusVoice study

    Lupus, Vol. 33, Núm. 7, pp. 663-674

  9. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study

    Molecular Cancer, Vol. 23, Núm. 1

  10. Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guidelines

    American Journal of Medicine, Vol. 137, Núm. 2, pp. 137-146.e10

  11. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy

    Therapeutic Advances in Medical Oncology, Vol. 16

  12. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

    Nature Medicine

  13. Trastuzumab deruxtecan in breast cancer

    Critical Reviews in Oncology/Hematology, Vol. 198

2023

  1. Burden of Illness beyond Mortality and Heart Failure Hospitalizations in Patients Newly Diagnosed with Heart Failure in Spain According to Ejection Fraction

    Journal of Clinical Medicine, Vol. 12, Núm. 6

  2. Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 9, pp. 2803-2811

  3. Differences in clinical outcomes, health care resource utilization and costs in heart failure patients according to left ventricular ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 11, pp. 862-871

  4. Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients with Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)

    Journal of Clinical Oncology, Vol. 41, Núm. 1, pp. 43-53

  5. Evolution of economic burden of heart failure by ejection fraction in newly diagnosed patients in Spain

    BMC Health Services Research, Vol. 23, Núm. 1

  6. Impact of standard modifiable cardiovascular risk factors on 2-year all-cause mortality: Insights from an international cohort of 23,489 patients with acute coronary syndrome

    American Heart Journal, Vol. 264, pp. 20-30

  7. Ravulizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

    Annals of Neurology, Vol. 93, Núm. 6, pp. 1053-1068